SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($0.79), $0.15 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $31.66 million versus the consensus estimate of $16.75 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.